10x Genomics news

Won $4.8M patent infringement verdict with all three patents upheld, strengthening IP portfolio in growing single-cell sequencing market. Potential for enhanced damages and permanent injunction in post-trial proceedings. However, stock declined 5% post-announcement, suggesting market skepticism about near-term impact.

Stock has surged 116% over the past year, significantly outperforming the S&P 500. Institutional investor (Quantedge Capital) increased stake by $4.25 million. Company showed improving fundamentals with 9% adjusted revenue growth, improved gross margins to 70%, reduced operating expenses by 15%, and launched Atera, described as the most significant product introduction in company history. Strong cash position of ~$540 million supports continued investment.

10x Genomics gained 12.2% over the past month despite reporting a revenue decline of 12.6% YoY and negative EPS of -$0.14. The stock has a Zacks Rank #3 (Hold) with minimal estimate revisions (-2%), suggesting market sentiment is cautiously balanced despite operational challenges.

Company is mentioned as part of the precision medicine ecosystem covered in the report, but no specific deal activity or performance metrics are discussed.

Company is listed as featured in the bioinformatics deals report, indicating active participation in partnerships, but no specific deal performance or outcomes are mentioned.

Company highlighted for expanding spatial biology capabilities and high-resolution spatial transcriptomics workflows in 2026, positioning it well in a growing market segment.

Innovative NGS technology provider listed among key industry players, positioned to benefit from growing demand for advanced sequencing solutions and precision medicine applications.

Strong long-term revenue growth (ninefold increase over 8 years) and leading Chromium platform position are offset by lack of profitability and weak 2026 guidance (0-4% growth), making it a mixed investment case.